MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim
Authors
Keywords
-
Journal
CELL BIOLOGY INTERNATIONAL
Volume 38, Issue 4, Pages 435-443
Publisher
Wiley
Online
2013-12-16
DOI
10.1002/cbin.10225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity
- (2013) D Min et al. BRITISH JOURNAL OF CANCER
- MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma
- (2013) Shibo Lin et al. Cancer Cell International
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- (2013) F. Catalanotti et al. CLINICAL CANCER RESEARCH
- Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions
- (2013) M. Courcelles et al. Molecular Systems Biology
- Long Noncoding RNA HOTAIR Is a Prognostic Marker for Esophageal Squamous Cell Carcinoma Progression and Survival
- (2013) Xiao-Bin Lv et al. PLoS One
- Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer
- (2013) Guang-Hui Liu et al. TUMOR BIOLOGY
- The Role of microRNAs in the Tumorigenesis of Ovarian Cancer
- (2013) Gianpiero Di Leva et al. Frontiers in Oncology
- MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene
- (2012) Xia Liu et al. CELL CYCLE
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
- (2012) Sapna P Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas
- (2012) E. Martin-Sanchez et al. HAEMATOLOGICA
- Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor
- (2012) Takumi Kawabata et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation
- (2012) G. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation
- (2011) Bjoern Chapuy et al. BRITISH JOURNAL OF HAEMATOLOGY
- CCL11-CCR3 Interactions Promote Survival of Anaplastic Large Cell Lymphoma Cells via ERK1/2 Activation
- (2011) T. Miyagaki et al. CANCER RESEARCH
- miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer
- (2011) Akihiko Tsuchida et al. CANCER SCIENCE
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- (2011) K. M. Kinross et al. MOLECULAR CANCER THERAPEUTICS
- miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro
- (2011) Xiao-Bin Lv et al. Chinese Journal of Cancer
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- MAP Kinase-Mediated c-fos Regulation Relies on a Histone Acetylation Relay Switch
- (2008) Amanda O'Donnell et al. MOLECULAR CELL
- Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM
- (2008) J A Wickenden et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started